Biopharmaceutical CDMO Market: Growth, Size, Share, and Trends

Report Code BT 8780
Published in Jul, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030

Overview

The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period.  The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.

Biopharmaceutical Contract Manufacturing Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Biopharmaceutical Contract Manufacturing Market

Asia Pacific

The growth of the market in the Asia Pacific region is driven by an increasing patient population, heightened interest in advanced treatments, and impending patent expirations of current biologics.

The biopharmaceutical contract manufacturing sector is primarily driven by an increase in approvals for biologics and a rise in chronic illnesses, particularly among the aging population.

The biopharmaceutical contract manufacturing market is expected to grow during the forecast period, driven by the increasing demand for precision treatments targeting chronic and rare conditions.

North America currently leads the global biopharmaceutical contract manufacturing market, and this trend is expected to continue throughout the projected period.

The Asia Pacific region is projected to register the highest growth rate, at a CAGR of 9.6% over the forecast period.

Global Biopharmaceutical Contract Manufacturing Market Dynamics

DRIVER: Growing trend of outsourcing biologics manufacturing by biopharmaceutical companies

The increased use of biologics in medicine has led to a rise in outsourcing, as specialized contract manufacturers possess the expertise and infrastructure to efficiently produce these complex treatments while adhering to strict quality regulations. Their deep knowledge in protein chemistry and biomanufacturing enables biopharmaceutical companies to collaborate effectively, speeding up the development and production of new therapies. This outsourcing reduces internal costs and mitigates risks, contributing to the growth of the biologics market.

RESTRAINT: Compliance challenges with regulatory reforms

Compliance with regulatory reforms is crucial in contract manufacturing, as innovator companies must share sensitive product details with contract manufacturers (CMOs), which poses risks of unauthorized use and infringement. Many pharmaceutical firms have recently outsourced basic manufacturing activities to CMOs, especially for complex biologics requiring specialized expertise. Trust and transparency in the relationship between pharmaceutical companies and CMOs are essential for this trend to succeed. Strong partnerships can benefit both parties while protecting intellectual property rights. Upholding regulatory reforms and mutual trust is vital for fostering long-term growth and innovation in pharmaceutical manufacturing, ensuring quality treatments for patients.

 

OPPORTUNITY: Rising demand for cell & gene therapy

Cell & gene therapies are emerging as targeted treatments for complex or rare conditions, filling gaps that traditional small-molecule drugs often cannot address. The surge in demand for specialized manufacturing services is evident, with 38 such therapies already approved by the US FDA in 2024. The increasing number of clinical trial candidates and the complexity of production highlight the need for dedicated manufacturing facilities. Many companies find it challenging to develop in-house capabilities, making contract manufacturing an essential resource to scale production, ensure quality, and meet regulatory standards. This trend is expected to drive significant growth in the contract manufacturing sector, solidifying its role in the future of cell & gene therapy.

CHALLENGES: Complexities in meeting reformed regulations

FDA regulations require manufacturers to closely follow guidelines from regulatory authorities. Contract Manufacturing Organizations (CMOs) face the complex task of obtaining approvals from different regions for the same molecule, often needing to customize submissions for each market. Minor errors can lead to significant delays, complicating access to regulated markets. Additionally, CMOs must adapt their manufacturing practices to evolving regulatory standards, maintaining expertise to ensure compliance across diverse regions. This pressure highlights their critical role in supporting pharmaceutical and biotech innovators from clinical trials to market commercialization.

Global Biopharmaceutical Contract Manufacturing Market Ecosystem Analysis

The biopharmaceutical contract manufacturing market consists of several key stakeholders, including pharmaceutical and biotechnology companies, academic and research institutions, and hospital and clinical laboratories. Key players in this ecosystem include biopharmaceutical contract manufacturing service providers, technology providers, data management and analysis providers, regulatory authorities (which ensure compliance and safety), and collaborative networks that promote knowledge sharing and cooperation. These stakeholders work together to advance base editing products and services, improve drug discovery processes, and develop new therapeutics.

Biopharmaceutical Contract Manufacturing Market
 

By service, the manufacturing segment commanded the largest market share in 2024.

The global biopharmaceutical contract manufacturing market is divided into several services, with manufacturing being the dominant segment due to its complexity. Producing biopharmaceuticals involves intricate processes that require precision and advanced technology. Many companies outsource their manufacturing needs to contract manufacturing organizations (CMOs) to remain competitive and adapt to evolving trends. These partnerships provide specialized expertise and facilities, allowing firms to focus on research and development while ensuring compliance with industry standards. This trend is driving growth in the outsourced manufacturing sector, particularly as the biologics market continues to expand globally.

By type, the biologic drug substance manufacturing segment accounted for the largest market share in 2024.

The global biopharmaceutical contract manufacturing market is divided into biologic drug substance and biologic drug product manufacturing. In 2024, biologic drug substance manufacturing accounted for the largest market share, driven by increased research on advanced treatments for complex illnesses. As traditional drugs lose patent protection, there is a shift toward targeted therapies like monoclonal antibodies and gene therapies, which require specialized equipment and advanced manufacturing technologies. Many companies are outsourcing to contract manufacturing organizations (CMOs) to access cutting-edge capabilities, reduce risk, and optimize costs, allowing them to focus on research and development. This trend is expected to fuel the growth of the global biologics contract manufacturing market as demand for precision therapies continues to rise.

The Asia Pacific is the fastest-growing regional market during the forecast period.

The biopharmaceutical contract manufacturing market is divided into six regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the fastest-growing market and is rapidly becoming an attractive hub for biopharmaceutical manufacturing. Key growth drivers include rising pharmaceutical R&D investments and government support for healthcare research. Many pharmaceutical companies are also outsourcing manufacturing to focus on their core capabilities. Additionally, the region's large population and increasing prevalence of chronic illnesses have created strong demand for innovative treatments and biologic drugs.

Asia Pacific's expanding healthcare infrastructure and favorable regulatory policies that streamline drug approvals further enhance its appeal for biopharmaceutical development. These factors position Asia Pacific as one of the fastest-growing markets in the industry, offering significant opportunities for both global and local players.

NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2024
ASIA PACIFIC: FASTEST-GROWING MARKET GLOBALLY
Biopharmaceutical Contract Manufacturing Market

Recent Developments of Biopharmaceutical Contract Manufacturing Market

  • In June 2025, WuXi Biologics announced the construction of a new microbial manufacturing facility for drug production (DP) in the Wenjiang district of Chengdu, with a capacity of 60,000 liters.
  • In October 2024, Samsung Biologics launched a high-concentration formulation platform aimed at accelerating the development of high-dose drugs.
  • In May 2024, Lonza acquired the large-scale biologics manufacturing site in Vacaville, California, from Roche.
  • In January 2023, WuXi Biologics entered into a licensing agreement with GSK Plc, granting GSK an exclusive global license to use WuXi Biologics’ proprietary technology platforms for the research, development, manufacturing, and commercialization of bispecific antibodies at the WuXi Biologics facility.

Key Market Players

Want to explore hidden markets that can drive new revenue in Biopharmaceutical Contract Manufacturing Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Service, Type, Source, Scale of Operation, Molecule Type, Therapeutic Area, and Region
Geographies covered North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Key Questions Addressed by the Report

Who are the key players in the biopharmaceutical contract manufacturing market?

The key players in the global biopharmaceutical contract manufacturing market are Lonza (Switzerland), WuXi Biologics (China), Samsung Biologics (South Korea), Thermo Fisher Scientific, Inc. (US), and AbbVie (US).

Which type segment dominates the biopharmaceutical contract manufacturing market?

The biologic drug substance manufacturing segment held the largest market share in 2024. Increasing research and development activities for the development of novel drugs are driving the growth of this market.

Which service segment dominates the biopharmaceutical contract manufacturing market?

The manufacturing segment held the largest share of the global biopharmaceutical contract manufacturing market in 2024. This is primarily due to the rising demand for biologics in the biopharmaceutical industry.

Which source segment of the biopharmaceutical contract manufacturing market is expected to dominate the market?

The mammalian expression systems segment held the largest share in 2024 due to increasing pipelines of mammalian-based biologics and the advantages of mammalian expression systems, like proven post-translational modifications, correct protein folding, and improved bioactivity.

What is the market size for the biopharmaceutical contract manufacturing market?

The biopharmaceutical contract manufacturing market is estimated to reach USD 34.15 billion by 2030 from USD 22.40 billion in 2025, at a CAGR of 8.8% during the forecast period of 2025 to 2030.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biopharmaceutical Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
34
RESEARCH METHODOLOGY
39
EXECUTIVE SUMMARY
52
PREMIUM INSIGHTS
56
MARKET OVERVIEW
60
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
    - Rising demand for biologics and biosimilars
    - Growing focus on personalized medicine
    - Increasing collaborations between pharmaceutical companies and biologics CMOs
    - Advancements in manufacturing technologies
    RESTRAINTS
    - Intellectual property rights issues
    OPPORTUNITIES
    - Rising demand for cell & gene therapy
    - Significant growth opportunities offered by emerging countries
    - Expansion of biologics manufacturing capacities by CMOs
    CHALLENGES
    - Strict regulations
  • 5.3 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Single-use technologies
    - Continuous bioprocessing
    COMPLEMENTARY TECHNOLOGIES
    - Robotics and automation in fill-finish
    - CRISPR & gene editing tools
    ADJACENT TECHNOLOGIES
    - 3D bioprinting & microfluidics
    - Biosensors & real-time analytics
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.5 PRICING ANALYSIS (QUALITATIVE)
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PATENT ANALYSIS
  • 5.9 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY LANDSCAPE
  • 5.10 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.11 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.13 INVESTMENT & FUNDING SCENARIO
  • 5.14 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • 5.15 IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACTMANUFACTURING MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    - US
    - Europe
    - APAC
    IMPACT ON UPSTREAM INDUSTRIES
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
97
  • 6.1 INTRODUCTION
  • 6.2 MANUFACTURING
    SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET
  • 6.3 FORMULATION & FILL-FINISH
    CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH
  • 6.4 PACKAGING & LABELING
    IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH
  • 6.5 OTHER SERVICES
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE
112
  • 7.1 INTRODUCTION
  • 7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING
    INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
  • 7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING
    INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
121
  • 8.1 INTRODUCTION
  • 8.2 COMMERCIAL OPERATIONS
    INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
  • 8.3 CLINICAL OPERATIONS
    INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE
130
  • 9.1 INTRODUCTION
  • 9.2 MAMMALIAN EXPRESSION SYSTEMS
    VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET
  • 9.3 NON-MAMMALIAN EXPRESSION SYSTEMS
    INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE
140
  • 10.1 INTRODUCTION
  • 10.2 MONOCLONAL ANTIBODIES
    GROWING APPROVALS FOR MABS TO PROPEL MARKET
  • 10.3 CELL & GENE THERAPY
    INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 10.4 ANTIBODY-DRUG CONJUGATES
    INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
  • 10.5 VACCINES
    INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
  • 10.6 THERAPEUTIC PEPTIDES & PROTEINS
    INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
  • 10.7 OTHER MOLECULES
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA
163
  • 11.1 INTRODUCTION
  • 11.2 ONCOLOGY
    INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
  • 11.3 AUTOIMMUNE DISEASES
    RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
  • 11.4 CARDIOVASCULAR DISEASES
    DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
  • 11.5 METABOLIC DISEASES
    INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
  • 11.6 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
  • 11.7 NEUROLOGY
    HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
  • 11.8 OTHER THERAPEUTIC AREAS
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
188
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Presence of large number of FDA-approved manufacturing facilities to favor market growth
    CANADA
    - Rising government funding for drug development to support market growth
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Rapidly growing pharmaceutical market to drive market
    UK
    - Rising investments in drug development to favor market growth
    FRANCE
    - Availability of funds from government and private organizations for domestic drug development to support market growth
    ITALY
    - Rising commercial drug development pipeline to drive market
    SPAIN
    - Rising R&D expenditure to propel market
    SWITZERLAND
    - Strong R&D investments and infrastructure expansion to bolster biotech manufacturing
    IRELAND
    - Robust R&D growth and CDMO capacity expansion to fuel pharma manufacturing
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Low manufacturing cost and high demand for medicines to favor market growth
    JAPAN
    - Growing demand for biosimilars to drive growth
    INDIA
    - Increasing pharma R&D activities and government funding for biotechnology industry to support market growth
    SOUTH KOREA
    - Increasing R&D activities for drug development to drive market
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Growing pharmaceutical industry to drive market
    MEXICO
    - Regulatory Improvements to support market growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Substantial opportunities fueled by strong government support to boost growth
    REST OF MIDDLE EAST
  • 12.7 AFRICA
    EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
283
  • 13.1 OVERVIEW
  • 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022−2025
  • 13.3 REVENUE ANALYSIS, 2020–2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Service type footprint
    - Molecule type footprint
    - Therapeutic area footprint
  • 13.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024
    - Detailed list of key SMEs/startups
    - Competitive benchmarking of key emerging players/startups
  • 13.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 13.8 BRAND/PRODUCT COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    SERVICE LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
304
  • 14.1 KEY PLAYERS
    LONZA
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    SAMSUNG BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    ABBVIE INC.
    - Business overview
    - Services offered
    CATALENT, INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Services offered
    - Recent developments
    FUJIFILM HOLDINGS CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Services offered
    - Recent developments
    GENSCRIPT BIOTECH CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    AGC INC.
    - Business overview
    - Services offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Services offered
    - Recent developments
    JSR CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    IDT BIOLOGIKA
    - Business overview
    - Services offered
    - Recent developments
    AJINOMOTO BIO-PHARMA
    - Business overview
    - Services offered
    - Recent developments
    AGILENT TECHNOLOGIES INC.
    - Business overview
    - Services offered
    - Recent developments
    ASAHI KASEI CORPORATION
    - Business overview
    - Services offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    ONESOURCE PHARMA SOLUTIONS
    RECIPHARM AB
    EMERGENT BIOSOLUTIONS
    SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
    LOTTE BIOLOGICS
    CURIA GLOBAL, INC.
    POLYPLUS TRANSFECTION
    ALDEVRON LLC
    MINAPHARM PHARMACEUTICALS
    RENTSCHLER BIOPHARMA SE
    PORTON PHARMA SOLUTIONS
    CELLARES, INC.
    MABPLEX INTERNATIONAL CO., LTD.
    ASYMCHEM INC.
APPENDIX
375
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
  • TABLE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 LIST OF KEY BIOSIMILARS APPROVED, 2023–2025
  • TABLE 6 LIST OF EXPANSIONS BY TOP COMPANIES
  • TABLE 7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM
  • TABLE 8 NUMBER OF PATENTS FILED IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
  • TABLE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INDICATIVE LIST OF PATENTS, 2022
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 COUNTRY-WISE REGULATORY SCENARIO FOR CONTRACT MANUFACTURING
  • TABLE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2025–2026)
  • TABLE 16 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
  • TABLE 18 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 21 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 22 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 23 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 24 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 25 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 33 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 39 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 40 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 45 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 46 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 48 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 MIDDLE EAST: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 52 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 MIDDLE EAST: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 58 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 59 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 65 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 67 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 69 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 70 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 71 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 72 TYPES OF MAMMALIAN EXPRESSION SYSTEMS
  • TABLE 73 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 79 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS
  • TABLE 80 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 82 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 86 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 87 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 92 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 93 FDA-APPROVED CAR T-CELL THERAPIES
  • TABLE 94 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 99 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 100 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 106 NIH FUNDING FOR VACCINE RESEARCH, 2018–2024 (USD MILLION)
  • TABLE 107 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 113 EXAMPLES OF PEPTIDE THERAPEUTICS
  • TABLE 114 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE
  • TABLE 115 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 117 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 120 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 121 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 123 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 126 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 127 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 128 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 129 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 130 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 132 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 133 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 134 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 136 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 139 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 140 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 142 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 144 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 145 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 146 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 148 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKETFOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 150 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 152 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 153 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 154 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 157 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 158 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 159 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 160 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 162 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 163 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION 2023–2030 (USD MILLION)
  • TABLE 164 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 166 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 170 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 171 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 172 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 174 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 175 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 176 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 178 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 179 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 180 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 181 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 182 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 183 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 184 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 185 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 186 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 187 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 188 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 189 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 190 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 191 EUROPE: KEY MACROINDICATORS
  • TABLE 192 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 193 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 194 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 195 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 196 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 197 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 198 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 199 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 200 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 201 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 202 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 203 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 204 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 205 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 206 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 207 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 208 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 209 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 210 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 211 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 212 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 213 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 214 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 215 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 216 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 217 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 218 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 219 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 220 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 221 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 222 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 223 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 224 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 225 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 226 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 227 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 228 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 229 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 230 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 231 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 232 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 233 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 234 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 235 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 236 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 237 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 238 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 239 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 240 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 241 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 242 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 243 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 244 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 245 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 246 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 247 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 248 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 250 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 251 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 252 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 255 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 256 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 257 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 258 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 259 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 260 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 261 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 262 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 263 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 264 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 265 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 266 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 267 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 268 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 269 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 270 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 271 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 272 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 273 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 274 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 276 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 277 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 278 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 285 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 286 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 287 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 288 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 289 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 290 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 291 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 292 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 293 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 294 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 295 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 296 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 297 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 298 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 299 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 300 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 301 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 302 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 303 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 304 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 305 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 306 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 307 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 308 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 309 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 310 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 311 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 312 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 313 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 314 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 315 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 316 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 317 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 318 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 319 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 321 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 322 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 323 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 324 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 325 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 326 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 327 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 328 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 329 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 330 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 331 AFRICA: KEY MACROINDICATORS
  • TABLE 332 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION)
  • TABLE 333 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 334 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
  • TABLE 335 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION)
  • TABLE 336 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION)
  • TABLE 337 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
  • TABLE 338 STRATEGIES DEPLOYED BY KEY PLAYERS
  • TABLE 339 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • TABLE 340 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
  • TABLE 341 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE TYPE FOOTPRINT
  • TABLE 342 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE TYPE FOOTPRINT
  • TABLE 343 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 344 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY SMES/STARTUPS
  • TABLE 345 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2024
  • TABLE 346 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
  • TABLE 347 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 348 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2022– JUNE 2025
  • TABLE 349 LONZA: COMPANY OVERVIEW
  • TABLE 350 LONZA: SERVICES OFFERED
  • TABLE 351 LONZA: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 352 LONZA: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 353 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 354 WUXI BIOLOGICS: SERVICES OFFERED
  • TABLE 355 WUXI BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 356 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022– JUNE 2025
  • TABLE 357 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
  • TABLE 358 SAMSUNG BIOLOGICS: SERVICES OFFERED
  • TABLE 359 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
  • TABLE 360 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 361 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 362 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 363 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
  • TABLE 364 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 365 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 366 ABBVIE INC.: SERVICES OFFERED
  • TABLE 367 CATALENT, INC.: COMPANY OVERVIEW
  • TABLE 368 CATALENT, INC.: SERVICES OFFERED
  • TABLE 369 CATALENT, INC.: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 370 CATALENT, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 371 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 372 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
  • TABLE 373 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
  • TABLE 374 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 375 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
  • TABLE 376 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 377 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 378 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 379 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 380 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 381 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
  • TABLE 382 GENSCRIPT BIOTECH CORPORATION: SERVICES OFFERED
  • TABLE 383 GENSCRIPT BIOTECH CORPORATION: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
  • TABLE 384 GENSCRIPT BIOTECH CORPORATION: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 385 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 386 ACG INC.: COMPANY OVERVIEW
  • TABLE 387 AGC INC.: SERVICES OFFERED
  • TABLE 388 AGC INC: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 389 AGC INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 390 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 391 MERCK KGAA: SERVICES OFFERED
  • TABLE 392 MERCK KGAA: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 393 MERCK KGAA: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 394 JSR CORPORATION: COMPANY OVERVIEW
  • TABLE 395 JSR CORPORATION: SERVICES OFFERED
  • TABLE 396 JSR CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 397 IDT BIOLOGIKA: COMPANY OVERVIEW
  • TABLE 398 IDT BIOLOGIKA: SERVICES OFFERED
  • TABLE 399 IDT BIOLOGIKA: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
  • TABLE 400 AJINOMOTO BIO-PHARMA: COMPANY OVERVIEW
  • TABLE 401 AJINOMOTO BIO-PHARMA: SERVICES OFFERED
  • TABLE 402 AJINOMOTO BIO-PHARMA: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 403 AGILENT TECHNOLOGIES INC.: COMPANY OVERVIEW
  • TABLE 404 AGILENT TECHNOLOGIES INC.: SERVICES OFFERED
  • TABLE 405 AGILENT TECHNOLOGIES INC.: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 406 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
  • TABLE 407 ASAHI KASEI CORPORATION: SERVICES OFFERED
  • TABLE 408 ASAHI KASEI CORPORATION: DEALS, JANUARY 2022–JUNE 2025
  • TABLE 409 ONESOURCE PHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 410 RECIPHARM AB: COMPANY OVERVIEW
  • TABLE 411 EMERGENT: COMPANY OVERVIEW
  • TABLE 412 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 413 LOTTE BIOLOGICS: COMPANY OVERVIEW
  • TABLE 414 CURIA GLOBAL, INC.: COMPANY OVERVIEW
  • TABLE 415 POLYPLUS TRANSFECTION: COMPANY OVERVIEW
  • TABLE 416 ALDEVRON LLC: COMPANY OVERVIEW
  • TABLE 417 MINAPHARM PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 418 RENTSCHLER BIOPHARMA SE: COMPANY OVERVIEW
  • TABLE 419 PORTON PHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 420 CELLARES, INC.: COMPANY OVERVIEW
  • TABLE 421 MABPLEX INTERNATIONAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 422 ASYMCHEM INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
  • FIGURE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
  • FIGURE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
  • FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024)
  • FIGURE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
  • FIGURE 11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
  • FIGURE 12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
  • FIGURE 13 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF BIOPHARMACEUTICAL CONTRACTMANUFACTURING MARKET
  • FIGURE 17 INCREASING APPROVALS OF BIOLOGICS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • FIGURE 18 COMMERCIAL OPERATIONS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
  • FIGURE 19 ONCOLOGY SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030
  • FIGURE 20 MONOCLONAL ANTIBODIES TO CONTINUE TO DOMINATE MARKET IN 2030
  • FIGURE 21 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DURING FORECAST PERIOD
  • FIGURE 22 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2024
  • FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM MAP
  • FIGURE 27 PATENT ANALYSIS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2014–DECEMBER 2024
  • FIGURE 28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES
  • FIGURE 30 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER
  • FIGURE 31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 32 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020–2024 (USD MILLION)
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET (2024)
  • FIGURE 36 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 37 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
  • FIGURE 38 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (SMES/STARTUPS), 2024
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 42 LONZA: COMPANY SNAPSHOT (2024)
  • FIGURE 43 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
  • FIGURE 44 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 46 ABBVIE INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 CATALENT, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
  • FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 51 SGENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 52 AGC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 54 JSR CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 55 AJINOMOTO BIO-PHARMA: COMPANY SNAPSHOT (2024)
  • FIGURE 56 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 57 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2024)

 

This research study extensively utilized secondary sources, directories, and databases to gather valuable information for analyzing the global biopharmaceutical contract manufacturing market. In-depth interviews were conducted with a variety of primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants. These interviews were essential for obtaining and verifying critical qualitative and quantitative information, as well as assessing the growth prospects of the market. The global market size estimated through secondary research was then validated and refined using inputs from primary research to determine the final market size.

Secondary Research

Secondary research was primarily utilized to gather information for a comprehensive study focused on the biopharmaceutical contract manufacturing market, emphasizing technical and commercial aspects. The sources consulted for this research included Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Bioprocess and Biosystems Engineering, Bioprocess International, PLOS Biology, European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), and World Journal of Pharmaceutical Sciences.

In addition to these sources, the study also included corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements. Other resources included business magazines, research journals, press releases, and information from trade, business, and professional associations, along with analyses from MarketsandMarkets. These sources were instrumental in acquiring essential information about key market players, classifications, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

Primary Research

After conducting an initial assessment of the global biopharmaceutical contract manufacturing market through secondary research, we carried out comprehensive primary research. This involved conducting in-depth interviews with experts from the demand side, including stakeholders from pharmaceutical and biotechnology companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and academic and research institutions.

Additionally, we interviewed key supply-side participants, such as C-suite executives, senior executives, product managers, and marketing and sales leaders from leading manufacturers, distributors, and channel partners. Our research focused on six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts.

Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to gain a comprehensive understanding of the market dynamics.

The following is a breakdown of the primary respondents:

Biopharmaceutical Contract Manufacturing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the biopharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the biopharmaceutical contract manufacturing market was generated.
  • The revenues generated from their services have been determined through annual reports and secondary sources (including paid databases).
  • The services were mapped according to market segments. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Global Biopharmaceutical Contract Manufacturing Market Size: Bottom-up and Top-down Approach

Biopharmaceutical Contract Manufacturing Market

Data Triangulation

After estimating the total market size, it was divided into several segments and subsegments. To refine the overall market analysis and obtain accurate statistics for each segment and subsegment, we employed data triangulation and market breakdown procedures wherever applicable. This involved studying various factors and trends from both the demand and supply sides to validate the findings.

Market Definition

Biopharmaceutical contract manufacturing involves outsourcing biological manufacturing services to specialized organizations known as contract manufacturing organizations (CMOs). Biologics are intricate pharmaceutical products derived from living organisms, including proteins, peptides, nucleic acids, cells or tissues, and other molecules produced through biotechnology. The market study encompasses an assessment of various services, sources, types, scales of operation, molecules, and therapeutic areas within the field of biopharmaceutical contract manufacturing.

Stakeholders

  • Pharmaceutical and Biotechnology Companies
  • Research and Consulting Firms
  • Academic Medical Centers
  • Government Research Organizations
  • Clinical Research Institutes
  • Contract Research Organizations
  • Pharmaceutical Distributors and Suppliers
  • Corporate Entities
  • Contract Development and Manufacturing Organizations

Report Objectives

  • To define, describe, and forecast the biopharmaceutical contract manufacturing market based on service, type, source, scale of operation, molecule type, therapeutic area, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the biopharmaceutical contract manufacturing market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments concerning six main regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global biopharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as service launches, expansions, agreements, and collaborations in the biopharmaceutical contract manufacturing market
  • To benchmark players within the biopharmaceutical contract manufacturing market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

 

Previous Versions of this Report

Biopharmaceutical CDMO Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2028

Report Code BT 8780
Published in Sep, 2023, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biopharmaceutical Contract Manufacturing Market

DMCA.com Protection Status